𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Membrane-covered stents for the treatment of aortocoronary vein graft disease

✍ Scribed by Stephan Baldus; Ralf Köster; Jacobus Reimers; Christian W. Hamm

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
313 KB
Volume
50
Category
Article
ISSN
1522-1946

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Membrane-covered stents: A new treatment
Membrane-covered stents: A new treatment strategy for saphenous vein graft lesions
✍ Stephan Baldus; Ralf Köster; Jacobus Reimers; Jan Kähler; Thomas Meinertz; Chris 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract The restenosis rate after stenting of lesions in aortocoronary venous bypass grafts still has to be considered unsatisfactorily high. We investigated a new stent design characterized by an expandable polytetrafluorethylene (PTFE) membrane in between two layers of struts. Five consecutiv

Percutaneous revascularization of an ext
Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent
✍ Gurbel, Paul A. ;Criado, Frank J. ;Curnutte, E. Alan ;Patten, Peggy ;Secada-Lovi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

A 68-year-old man developed unstable angina 12 years following coronary artery bypass surgery. Angiography revealed an extensive area of severe stenosis and diminished distal flow in a right coronary artery vein bypass graft. Given the high distal embolism rate associated with conventional catheter-

Autologous vein graft-coated stents for
Autologous vein graft-coated stents for the treatment of thrombus-containing coronary artery lesions
✍ Stefanadis, Christodoulos ;Tsiamis, Eleftherios ;Vlachopoulos, Charalambos ;Tout 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB 👁 2 views

Recent studies have shown that stents may have a potential role in the treatment of thrombus-containing lesions. We report on the application of an autologous vein graft-coated stent (AVGCS) as the primary therapeutic modality for acute myocardial infarction in 10 patients. AVGCS delivery and deploy